Akut mieloid leukémia (AML): vizsgálatok itt: Németország

44 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

• 1. fázisTaking people
  Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

  Where

  Tübingen

  Életkor

  18 év and over

  People

  20

  Run by

  University Hospital Tuebingen

  See details and how to joinNCT06252584
• 1. fázisTaking people
  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  Where

  Berlin, Munich, Ulm

  People

  225 worldwide

  Run by

  Janssen Cilag International

  See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
• 3. fázisTaking people
  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  Where

  Aachen, Berlin, Bochum, Bonn, Bremen, Brunswick, Chemnitz, Dortmund, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Greifswald, Halle (Saale), Hamburg, Hanover, Heidelberg, Heilbronn, Homburg, Jena, Karlsruhe, Ludwigshafen Am Rhein, Magdeburg, Mainz, Marburg, Minden, Munich, Nuremberg, Oldenburg, Passau, Regensburg, Rostock, Stuttgart, Ulm, Wuppertal

  Életkor

  18 év and over

  People

  875 worldwide

  Run by

  Stichting Hemato-Oncologie voor Volwassenen Nederland

  See details and how to joinNCT07223814 · EU 2025-522767-15-00
• 1. fázisTaking people
  A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

  Where

  Berlin, Munich

  Életkor

  18 év and over

  People

  40 worldwide

  Run by

  Charm Therapeutics

  See details and how to joinNCT07751991 · EU 2026-526409-14-00
• 3. fázisTaking people
  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  Where

  Arnsberg, Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Dortmund, Frankfurt Am Main, Giessen, Goch, Greifswald, Halle (Saale), Hamburg, Hamm, Hannover, Hanover, Heilbronn, Herne, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Ludwigshafen Am Rhein, Magdeburg, Mainz, Minden, Munich, Offenburg, Oldenburg, Regensburg, Rostock, Stuttgart, Traunstein, Trier, Tuebingen, Ulm, Villingen-Schwenningen, Wuppertal

  Életkor

  18 év to 75 év

  People

  650 worldwide

  Run by

  University of Ulm

  See details and how to joinNCT04628026 · EU 2023-507518-28-00
• 3. fázisTaking people
  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  Where

  Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, Leipzig, München, Würzburg

  Életkor

  18 év and over

  People

  600 worldwide

  Run by

  Janssen Research & Development, LLC

  See details and how to joinNCT06852222 · EU 2024-520154-38-00
• 3. fázisTaking people
  Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  Where

  Freiburg im Breisgau, Halle, Jena, Leipzig, Munich

  Életkor

  18 év to 75 év

  People

  366 worldwide

  Run by

  Priothera SAS

  See details and how to joinNCT05429632
• No phaseTaking people
  Master Framework For Relapse or Refractory Acute Myeloid Leukemia

  Where

  Aachen, Greifswald, Halle, Rostock

  Életkor

  6 év and over

  People

  4000 worldwide

  Run by

  Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

  See details and how to joinNCT06459024
• 3. fázisTaking people
  IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

  Where

  Aachen, Greifswald, Halle (Saale), Halle Saale, Rostock, Zwickau

  Életkor

  18 év and over

  People

  339 worldwide

  Run by

  Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

  See details and how to joinNCT06713837 · EU 2024-514517-35-00
• 1/2. fázisTaking people
  Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  Where

  Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm

  Életkor

  16 év and over

  People

  85 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07155226 · EU 2025-521299-76-00
• 3. fázisTaking people
  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  Where

  Berlin, Bochum, Bonn, Bremen, Brunswick, Flensburg, Freiburg im Breisgau, Halle Saale, Hamburg, Hanover, Heilbronn, Homburg, Karlsruhe, Mainz, Minden, Munich, Oldenburg, Regensburg, Stuttgart, Tuebingen, Ulm

  Életkor

  18 év and over

  People

  180 worldwide

  Run by

  Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

  See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
• 3. fázisTaking people
  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  Where

  Brunswick, Chemnitz, Duesseldorf, Hamburg, Heidelberg, Herne, Jena, Leipzig, Minden, Stuttgart, Tuebingen

  Életkor

  12 év and over

  People

  468 worldwide

  Run by

  Syndax Pharmaceuticals

  See details and how to joinNCT07211958 · EU 2025-522279-27-00
• 3. fázisTaking people
  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  Where

  Aachen, Bad Saarow, Berlin, Cottbus, Frankfurt Am Main, Halle Saale, Homburg, Leipzig, Mainz, Muenster, Munich

  Életkor

  18 év and over

  People

  1300 worldwide

  Run by

  Kura Oncology, Inc.

  See details and how to joinNCT07007312 · EU 2025-521314-25-00
• 1/2. fázisTaking people
  A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  Where

  Hamburg, Leipzig, Mainz, Ulm

  Életkor

  30 nap and over

  People

  447 worldwide

  Run by

  Syndax Pharmaceuticals

  See details and how to joinNCT04065399 · EU 2024-513759-34-00
• 2/3. fázisTaking people
  A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  Where

  Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg

  Életkor

  18 év and over

  People

  316 worldwide

  Run by

  Taiho Oncology, Inc.

  See details and how to joinNCT04256317 · EU 2024-515098-93-00
• 4. fázisTaking people
  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  Where

  Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm

  Életkor

  18 év and over

  People

  365 worldwide

  Run by

  Medizinische Hochschule Hannover

  See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
• 1. fázisTaking people
  Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)

  Where

  Berlin, Dresden, Essen, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Marburg, Munich, Ulm, Wuerzburg

  Életkor

  18 év and over

  People

  37 worldwide

  Run by

  AvenCell Europe GmbH

  See details and how to joinNCT05949125 · EU 2022-501797-19-00
• 1/2. fázisTaking people
  Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

  Where

  Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich

  Életkor

  18 év and over

  People

  38

  Run by

  Heinrich-Heine University, Duesseldorf

  See details and how to joinNCT05807932 · EU 2024-514688-24-00
• 2. fázisTaking people
  (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  Where

  Aachen, Freiburg im Breisgau, Lübeck, Mannheim

  Életkor

  18 év and over

  People

  140 worldwide

  Run by

  Cogent Biosciences, Inc.

  See details and how to joinNCT04996875 · EU 2024-511407-42-00
• 1/2. fázisTaking people
  A Study of BGB-11417 in Participants With Myeloid Malignancies

  Where

  Leipzig, Ulm

  Életkor

  18 év and over

  People

  260 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT04771130 · EU 2023-508881-14-00
• 3. fázisTaking people
  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  Where

  Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Essen, Flensburg, Freiburg im Breisgau, Greifswald, Halle (Saale), Hamburg, Hanover, Heilbronn, Herne, Homburg, Karlsruhe, Magdeburg, Mainz, Minden, Munich, Oldenburg, Potsdam, Regensburg, Stuttgart, Tuebingen, Ulm, Wuppertal

  Életkor

  18 év and over

  People

  448 worldwide

  Run by

  Stichting Hemato-Oncologie voor Volwassenen Nederland

  See details and how to joinNCT06652438 · EU 2024-512733-32-00
• 2. fázisTaking people
  Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

  Where

  Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, Jena, Kiel, Leipzig, Mainz, Münster, Nuremberg, Rostock, Stuttgart

  Életkor

  18 év and over

  People

  220

  Run by

  Technische Universität Dresden

  See details and how to joinNCT07025824
• 2. fázisTaking people
  Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

  Where

  Aachen, Augsburg, Bamberg, Bielefeld, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Halle (Saale), Heidelberg, Hildesheim, Kiel, Leipzig, Mannheim, Marburg, Muenster, Munich, Nuremberg, Regensburg, Stuttgart, Wiesbaden

  Életkor

  18 év to 70 év

  People

  146

  Run by

  Technische Universität Dresden

  See details and how to joinNCT05904106 · EU 2024-515267-59-00
• 2. fázisTaking people
  Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

  Where

  Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mainz, Mannheim, Muenster, Munich, Oldenburg, Rostock, Ulm

  Életkor

  18 év to 75 év

  People

  76

  Run by

  Technische Universität Dresden

  See details and how to joinNCT06717958 · EU 2023-509055-14-00
• 1. fázisTaking people
  Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  Where

  Hanover

  Életkor

  18 év and over

  People

  171 worldwide

  Run by

  Kura Oncology, Inc.

  See details and how to joinNCT06001788 · EU 2023-510288-37-00